Compare · ARGX vs PLUR
ARGX vs PLUR
Side-by-side comparison of argenx SE (ARGX) and Pluri Inc. (PLUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and PLUR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 3532.7x PLUR ($17.9M).
- ARGX has been more active in the news (11 items in the past 4 weeks vs 5 for PLUR).
- ARGX has more recent analyst coverage (25 ratings vs 0 for PLUR).
- Company
- argenx SE
- Pluri Inc.
- Price
- $1019.71+0.82%
- $1.67-5.65%
- Market cap
- $63.27B
- $17.9M
- 1M return
- -
- +0.00%
- 1Y return
- -
- -69.19%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 11
- 5
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest PLUR
- Director Shorrer Doron was granted 31,569 shares, increasing direct ownership by 474% to 38,228 units (SEC Form 4)
- Director Manieu Alexandre Weinstein was granted 180,000 shares, increasing direct ownership by 1,671% to 190,769 units (SEC Form 4)
- Pluri Inc. filed SEC Form 8-K: Other Events
- Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
- Ever After Foods Acquires Fishway to Expand Integrated Food Production Technology Platform
- Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
- Pluri Inc. filed SEC Form 8-K: Other Events
- Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
- Pluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- New insider Shorrer Doron claimed ownership of 13,628 shares (SEC Form 3)